Dr. Bradley Michael Haverkos, MD

Dr. Haverkos practices at UCHealth University of Colorado Hospital in Aurora, Colorado, part of UCHealth.

Dr. Haverkos' NPI, 1679707319, was assigned on May 10, 2009. Dr. Haverkos graduated from Wright State University Boonshoft School of Medicine in 2009. Dr. Haverkos holds Colorado license DR.0055435.

Dr. Haverkos' primary practice is UCHealth University of Colorado Hospital, at 12605 E 16th Ave, Aurora, CO 80045 in Adams County. The practice phone is (720) 848-0000.

Dr. Haverkos' primary practice is UCHealth University of Colorado Hospital in Aurora, Colorado, part of UCHealth. Dr. Haverkos is also affiliated with Children's Hospital Colorado Anschutz Medical Campus. The medical group on file is University of Colorado Medicine (CU Medicine). Dmand AI also links Dr. Haverkos to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Haverkos practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Haverkos' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Haverkos' licenses on file in 2 states: Colorado and Ohio.

CMS data shows 482 Medicare services from Dr. Haverkos across 5 procedure codes in 2024, for 163 Medicare patients. Medicare paid $48,539 for them.

CMS counts 163 Medicare patients who saw Dr. Haverkos in 2024. The largest group is 65 to 74, with 80 patients. 67% of them have high cholesterol, and 63% have high blood pressure. 13% are also on Medicaid. Their average risk score is 2.92, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Haverkos' median patient age at 70, with 42% women.

In 2024, Dr. Haverkos wrote 812 Medicare Part D claims for 95 patients. 81% of them were for generic drugs. CMS names the drug for 644 of them, across 20 drugs with 11 or more claims each, at $1,299,373 in total drug cost. In 2023, CMS named 561 claims across 16 drugs.

Dr. Haverkos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Haverkos as offering telehealth.

Dmand AI links 49 papers to Dr. Haverkos, published from 2014 to 2024. 2024 was the busiest year, with 5. The most frequent topics are Lymphoma, T-Cell, Peripheral, Herpesvirus 4, Human and Lymphoma, Large B-Cell, Diffuse. Dr. Haverkos has published most often in Blood Adv. Dr. Haverkos' most frequent co-authors are Manali K. Kamdar, MD, Robert A. Baiocchi, MD and Narendranath Epperla, MD.

Dmand AI links Dr. Haverkos to 4 clinical trials, 2 of them phase 1/2 studies. 1 is still active or recruiting. Conditions studied include Enteropathy-Associated T-Cell Lymphoma, Lymphatic Diseases and Lymphoma, Mantle-Cell.

CMS Open Payments shows 175 general payments to Dr. Haverkos from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 75% of the total. Kyowa Kirin, Inc. paid the most, $38,908.

Dr. Haverkos graduated from Wright State University Boonshoft School of Medicine in 2009.